| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.PGP.0000130446.84670.93 |
| P698 | PubMed publication ID | 15213595 |
| P50 | author | C. Blake Gilks | Q90823350 |
| P433 | issue | 3 | |
| P304 | page(s) | 200-205 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | International Journal of Gynecological Pathology | Q15746551 |
| P1476 | title | Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data | |
| P478 | volume | 23 |
| Q36380704 | 'BRCAness' and its implications for platinum action in gynecologic cancer |
| Q36614490 | A distinct molecular profile associated with mucinous epithelial ovarian cancer. |
| Q37133800 | A serum based analysis of ovarian epithelial tumorigenesis |
| Q42938103 | Choriocarcinoma arising in a serous carcinoma of ovary: an example of histopathology driving treatment |
| Q102141700 | Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan |
| Q36131119 | Comparative proteome analysis of human epithelial ovarian cancer. |
| Q79825860 | Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma |
| Q92433614 | Concurrent high-grade serous carcinoma and borderline tumor demonstrating different chemo-sensitivity |
| Q37232123 | Critical molecular abnormalities in high-grade serous carcinoma of the ovary |
| Q26852127 | Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR) |
| Q36673528 | Differential gene expression identifies subgroups of ovarian carcinoma |
| Q53325005 | Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. |
| Q37564665 | Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines |
| Q26822730 | HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies |
| Q33517907 | HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy |
| Q38687061 | High-grade serous carcinoma of tubo-ovarian origin: recent developments. |
| Q35510378 | Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum |
| Q34271218 | Lipid index changes in the blood serum of patients with hyperplastic and early neoplastic lesions in the ovaries |
| Q38068618 | Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles |
| Q37301334 | Low-grade serous ovarian cancer: a unique disease |
| Q83597688 | Low-grade serous primary peritoneal carcinoma |
| Q38067436 | Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates |
| Q47254055 | Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. |
| Q36681565 | Morphological and molecular basis of ovarian serous carcinoma |
| Q34729698 | Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum |
| Q38788240 | Obesity and Ovarian Cancer |
| Q40344519 | Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer |
| Q82238526 | Ovarian cancer |
| Q33807748 | Ovarian cancer: pathology, biology, and disease models |
| Q21563402 | Ovarian carcinoma subtypes are different diseases: implications for biomarker studies |
| Q36796282 | Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer |
| Q39872610 | Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs |
| Q37479727 | RETRACTED: Investigation of the hub genes and related mechanism in ovarian cancer via bioinformatics analysis |
| Q83636947 | Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant |
| Q37362164 | Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery |
| Q47982714 | Serum endocan levels in endometrial and ovarian cancers. |
| Q34173704 | Symptom presentation in invasive ovarian carcinoma by tumor histological type and grade in a multiethnic population: a case analysis |
| Q35634450 | Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms |
| Q38165164 | Targeted therapies and clinical trials in ovarian cancer |
| Q82674487 | The heterogeneity of epithelial ovarian cancer: getting it right |
| Q37118142 | The impact of T-cell immunity on ovarian cancer outcomes |
| Q34695404 | Unmasking the complexities of mucinous ovarian carcinoma |
| Q61853673 | Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium |
| Q52861155 | [Grading of gynecological tumors : Current aspects]. |
Search more.